English | 简体中文 | 繁體中文 | 한국어 | 日本語
Sunday, 20 September 2020, 13:13 HKT/SGT
Share:
Mitsubishi Chemical: Has developed new electrolyte for Tesla. The solvents and solute are supplied from Shida Shenghua

HONG KONG, Sept 20, 2020 - (ACN Newswire) - A Mitsubishi Chemical (MTLHY) technical expert revealed that the important innovations of Tesla's new battery are the positive and negative electrodes and the new electrolyte. Mitsubishi Chemical has perfectly matched the electrolyte technology for the new battery. This electrolyte mainly uses new solutes and functional additives, which can greatly improve battery performance. The technical expert said that the solvent in the new electrolyte is still supplied by the Chinese company Shida Shenghua, and the amount of DMC in the solvent will be greatly increased. Beginning in 2017, Mitsubishi and Shida Shenghua have jointly developed a new type of solute. This product will soon be mass-produced, which can effectively increase battery cycle times and energy density.


Topic: Press release summary
Source:

Sectors: Daily Finance, Chemicals, Energy, Daily News
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
X World Games Secures $1.2 Million Funding led by Top Crypto Venture Funds  
May 8, 2021 00:00 HKT/SGT
Blockchain and Liberty for All  
May 7, 2021 19:16 HKT/SGT
Butterfly Protocol Announces New Program to Allow Full Blockchain Top-Level Domain Sponsorship and Control  
May 7, 2021 18:28 HKT/SGT
ACDX Offers World's First Leveraged Trading for Chia (XCH)  
May 7, 2021 16:17 HKT/SGT
Global Internet of People Inc. Posts Robust 2020 Business Growth  
May 7, 2021 15:00 HKT/SGT
Don Muang Tollway (SET:DMT) begins stock trading on SET  
May 7, 2021 14:00 HKT/SGT
Moonstake Partners with IOST Blockchain, Soon to Enable Support for IOST Staking  
May 7, 2021 12:00 HKT/SGT
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications   
May 7, 2021 10:08 HKT/SGT
China Marks an Important Year of Promoting Carbon Neutrality  
May 7, 2021 00:00 HKT/SGT
Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand  
May 7, 2021 00:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575